51 results about "Poly d l lactide" patented technology

Coatings are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one layer of poly(lactide-co-caprolactone) copolymer on the bonded lactone. Biologically active agents may be disposed with the poly(lactide-co-caprolactone) copolymer layers. Such coated surfaces may be useful in medical devices, in particular stents.

The present invention provides a composition comprising: (a) dielectric material; and (b) porogen comprising at least two fused aromatic rings wherein each of the fused aromatic rings has at least one alkyl substituent thereon and a bond exists between at least two of the alkyl substituents on adjacent aromatic rings. Preferably, the dielectric material is a composition comprising (a) thermosetting component comprising (1) optionally monomer of Formula I as set forth below and (2) at least one oligomer or polymer of Formula II as set forth below where Q, G, h, I, I, and w are as set forth below and (b) porogen. Preferably, the porogen is selected from the group consisting of unfunctionalized polyacenaphthylene homopolymer, functionalized polyacenaphthylene homopolymer, polyacenaphthylene copolymer, polynorbornene, polycaprolactone, poly(2-vinylnaphthalene), vinyl anthracene, polystyrene, polystyrene derivatives, polysiloxane, polyester, polyether, polyacrylate, aliphatic polycarbonate, polysulfone, polylactide, and blends thereof. The present compositions are particularly useful as dielectric substrate material in microchips, multichip modules, laminated circuit boards, and printed wiring boards.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and / or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

The present invention provides a composition comprising: (a) dielectric material; and (b) porogen comprising at least two fused aromatic rings wherein each of the fused aromatic rings has at least one alkyl substituent thereon and a bond exists between at least two of the alkyl substituents on adjacent aromatic rings. Preferably, the dielectric material is a composition comprising (a) thermosetting component comprising (1) optionally monomer of Formula I as set forth below and (2) at least one oligomer or polymer of Formula II as set forth below where Q, G, h, I, I, and w are as set forth below and (b) porogen. Preferably, the porogen is selected from the group consisting of unfunctionalized polyacenaphthylene homopolymer, functionalized polyacenaphthylene homopolymer, polyacenaphthylene copolymer, polynorbornene, polycaprolactone, poly(2-vinylnaphthalene), vinyl anthracene, polystyrene, polystyrene derivatives, polysiloxane, polyester, polyether, polyacrylate, aliphatic polycarbonate, polysulfone, polylactide, and blends thereof. The present compositions are particularly useful as dielectric substrate material in microchips, multichip modules, laminated circuit boards, and printed wiring boards.

The invention discloses a polylactide containing a side hydroxy or side carboxy functional group and a preparation method thereof. According to the preparation method, a polylactide with a functionalized norbornene-containing side group and a mercapto compound undergo mercapto-alkene click chemical reaction to form the polylactide containing the side hydroxy or side carboxy functional group. The preparation method for the polylactide is simple, quick and low in cost; a plurality of hydrophilic polar active groups are introduced to the main chain through norbornene, so that the prepared polylactide has multiple structures, high degradability, strong hydrophilic property and many active groups; and when the polylactide serving as a medicament carrier is applied to preparation of a pro-medicament, the prepared pro-medicament is high and controllable in medicament loading rate and good in hydrophilic property, can be completely degraded, contains groups capable of being modified again and has great scientific research and economic value.

The invention provides hydrogel which comprises the following raw materials in parts by weight: 1-50 parts of chitosan, 0.1-20 parts of a cross-linking agent and 10-100 parts of water, wherein the cross-linking agent comprises the following raw materials in parts by weight: 1-5 parts of a raw material A and 0.1-5 parts of a raw material B; after the raw material A is combined with the raw material B, a raw material C is connected with the final end of the mixture; the raw material A is polyethylene glycol; the raw material B is a degradable polymer; the raw material B is selected from one or more of polyglycollide, polylactide, polyglycollide lactide and polycaprolactone; and the raw material C is selected from one or more of glyoxylic acid, uronic acid and aldehyde benzoic acid. The invention further provides a preparation method of the hydrogel. The hydrogel has the beneficial effects that a reaction product of polyethylene glycol and the degradable polymer is enabled to react with glyoxylic acid, uronic acid and aldehyde benzoic acid, and the obtained cross-linking agent and chitosan form the hydrogel automatically in a solution.

The invention relates to a method for obtaining polylactide polyol by a way of ring-opening polymerization of lactide with lactide and a polyol as direct raw materials. The method includes the following steps: A, lactide purification: a crude product lactide is purified, and lactide with the content of more than 99.5% and the optical purity of more than 99% is obtained; B, synthesis of polylactide polyol: the purified lactide and the polyol are added into a reaction kettle, then a catalyst is added according to a lactide weight ratio of 0.5 / 1000-1 / 1000 into the reaction kettle for polymerization, and polylactide polyol with the viscosity average molecular weight of 100-5000 is obtained, wherein the catalyst is a composite catalyst comprising one or more of zinc lactate, zinc oxide, zinc powder, diethyl zinc, tin lactate, tin oxide, tin dioxide, stannous oxide, stannous lactate, stannous octoate, stannous chloride, tin powder, propionic acid or tetrabutyl titanate. The method has simple process and easy operation, is suitable for industrialized production applications, and has no 'three wastes' emissions.

A macromer based novel copolymer comprising an acrylate or methacrylate ester of low molecular weight oligomeric lactide copolymerized with basic monomer is provided. These copolymers show unusual dissolution behavior in that they are soluble over a wide range of pH from 1.8 to 7.4. This unexpected solubility behavior can be exploited to develop pharmaceutical dosage forms.

The invention discloses a sustained-release microsphere to achieve the aims of contraception and long-term treatment of endometriosis uterine, which comprises the following components: (1) nomegestrol acetate or analogs thereof, and (2) a biodegradable polymer, wherein the weight ratio of an ester-terminated polymer to a carboxyl-terminated polymer is between 1:0.01-1:1; the ester-terminated polymer is selected from polylactide-glycolide, polylactide, poly-beta-hydroxybutyrate, poly ortho ester, polycaprolactone, poly-phosphate, polyanhydride, or poly-cyanoacrylate; the carboxyl-terminated polymer is selected from polyglycolic acid and polylactic acid-glycolic acid; and the weight of the nomegestrol acetate or the analogs thereof accounts for 5 to 80 percent of the total weight of the microsphere. The invention also discloses a preparation method and application of the sustained-release microsphere.

The invention provides a preparation method of a polylactide-type polyurethane-modified polylactic acid alloy. The preparation method comprises the following steps: a. dissolving D-polylactide polylol, diisocyanate and a catalyst in a mole ratio of 1:(3-5):(0.001-0.01) in a solvent, and reacting in a protective gas atmosphere at 50-100 DEG C to obtain a prepolymer; b. adding a chain extender into the prepolymer, and carrying out chain extension to obtain a D-polylactide polylol polyurethane elastomer, wherein the mole ratio of the chain extender to the D-polylactide polylol is (2-4):1; and c. premixing 60-99.5 parts by mass of polylactic acid and 0.5-40 parts by mass of D-polylactide polylol polyurethane elastomer, and carrying out melt extrusion at 175-190 DEG C through a double-screw extruder. The invention also provides a polylactide-type polyurethane-modified polylactic acid alloy.

Novel absorbable polymeric blends made from components wherein at least one of the components is synthesized using mixtures of mono- and di-functional initiators are disclosed. The blends have a first component that is a polylactide polymer or a copolymer of lactide and glycolide and a second component that is either poly(p-dioxanone) homopolymer, or a poly(p-dioxanone-co-glycolide) copolymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel absorbable medical devices made from these novel polymer blends, as well as novel methods of manufacture.

A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).

The invention discloses a degradable biological-based waterborne emulsion and a preparation method thereof. The preparation method comprises the following steps: carrying out a polymerization reaction on purified L-lactide, epsilon-caprolactone and polyol under the action of a catalyst, to obtain hydroxyl-terminated polyester polyol with the viscosity average molecular weight of 1000-10000; carrying out a reaction of hydroxyl-terminated polyester polyol, diisocyanate and a hydrophilic chain extender under the action of a catalyst, to obtain a prepolymer; and adding an emulsifier and water in the prepolymer, carrying out high-speed stirring emulsification, and carrying out a reaction with a crosslinking agent, to obtain the degradable waterborne emulsion. The degradable biological-based emulsion and the preparation method thereof are novel; the polylactide and caprolactone random copolymer which can be fully biodegradable is obtained, has relatively low glass transition temperature (Tg), has better emulsifying dispersion than polylactide, does not contain organic solvents, is biodegradable, can be widely applied in coatings, adhesives, fabric coating layers and other fields, is a quite good environmental-protection material, and has broad market prospects.

At least three component, body-implantable, absorbable, biocompatible, putty, and non-putty pain-relieving compositions for use in surgery comprising in intimate admixture: an analgesic having local pain-relieving activity for internal relief of pain, a finely powdered bulking material, preferably less than 50 microns, e.g. the metal salts of fatty acid, hydroxyapatite, DBM, polyglycolide, polylactide, polycaprolactones, absorbable glasses, gelatin, collagens, mono, and polysaccharides starches.An organic liquid capable of solubilizing, dispensing or suspending the analgesic, such as esters of monohydric alcohols with aliphatic monocarboxylic acids; C2-C18 monohydric alcohols with polycarboxylic acids; C8-C30 monohydric alcohols; tocopherol and esters thereof with mono or polycarboxylic acids; free carboxylic acids such as oleic, capric, and lauric; dialkyl ethers and ketones; polyhydroxy compounds and esters and ethers thereof; random or block copolymers of ethylene oxide and propylene oxide.

Process for increasingly producing D-Lactide and meso lactide by depolymerizing by back biting polylactide (PLA) said process which comprises: (i) Depolymerizing polylactide into its corresponding dimeric cyclic esters by heating the polylactide in the presence of a catalyst system comprising a catalyst and a co-catalyst in a reaction zone at temperature and pressure at which the polylactide is molten; (ii) Forming a vapor product stream from the reaction zone; (iii) Removing the vapor product stream and optionally condense it; (iv) Recovering, either together or separately meso-lactide, D- lactide and L-lactide.

A composition in a water-in-oil-in-water (W / O / W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising H2O; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W / O / W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W / O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-ε-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

The invention provides a curcumin micelle drug delivery system, a preparation method thereof and application of the curcumin micelle drug delivery system in treating tumor diseases. The drug delivery system is prepared from, by mass, 80-99.9% of amphiphilic segmented copolymer and 0.1-20% of curcumin. The amphiphilic segmented copolymer comprises a hydrophilic chain segment and a hydrophobic chain segment, wherein polyethylene glycol with the molecular weight of 100-6000 or methoxy polyethylene glycol with the molecular weight of 300-6000 serves as the hydrophilic chain segment, polylactide with the molecular weight of 200-6000 serves as the hydrophobic chain segment, the hydrophobic chain segment is subjected to end capping through groups containing fmoc and / or amino acid containing benzene ring structures, and the weight ratio of polyethylene glycol or methoxy polyethylene glycol to polylactide is (0.1-30):1. The invention further provides application of the drug delivery system in preparing tumor treating drugs.

The invention relates to a sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers. In other words, the present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).

The invention discloses a pyrrolidyl amino bidentate ligand aluminum complex, a preparation method thereof and application thereof in catalyzing polymerization of lactone. The preparation method comprises the following steps of: directly reacting a neutral pyrrolidyl amino bidentate ligand with an alkyl aluminum compound; and filtering, concentrating and recrystallizing to obtain the target compound from reaction products. The pyrrolidyl amino bidentate ligand aluminum complex is a high-efficiency catalyst for ring-opening polymerization of the lactone, can be used for polymerization reaction of lactide, epsilon-caprolactone and the like. The pyrrolidyl amino bidentate ligand aluminum complex has the obvious advantages that: raw materials are readily available; the synthetic route is simple; the product has high yield, stable properties and higher catalytic activity; poly(L-lactide) and poly(epsilon-caprolactone) with high molecular weight and narrow molecular weight distribution can be obtained; and the requirement of the industrial department can be met. The structural formula of the complex is shown as the description.

The invention provides degradable photosensitive phosphate copolymers, belonging to the technical field of functional polymer materials. According to the invention, ethyl dichlorophosphate (EDP), caprolactone (CL) and lactide (LA) are used as monomers, bishydroxyl-terminated polycaprolactone (PCL) and polylactide (PLA) are used as raw materials, and melt-phase polycondensation are carried out to prepare a series of phosphate copolymers PPE-PCL and PPE-PLA; then through further chemical modification, a cinnamoyl group is introduced to the tail end of a polymer chain so as to prepare the photosensitive phosphate copolymers PPE-PCL-C and PPE-PLA-C. A micelle prepared by self-assembling of the phosphate polymers in a mixed medium has certain degradability and photosensitivity. The polymers prepared in the invention have good biodegradability and biocompatibility and can be applied to biomedical fields like drug delivery and tissue engineering.

An aliphatic polylactone intermingled material as medicine releasing system contains hydrophilic medicine (1-30 wt. portions) and medicine carrier (100 wt. portions). The mentioned hydrophilic medicine may be 5-fluorouracil, streptomycin, growth factor, etc.. The mentioned carrier is the mixture of PLA, PGA, PCL, PHB, or PHV. Its advantage is constant-speed sustained releasing.

Novel absorbable polymeric blends made from components wherein at least one of the components is synthesized using mixtures of mono- and di-functional initiators are disclosed. The blends have a first component that is a polylactide polymer or a copolymer of lactide and glycolide and a second component that is either poly(p-dioxanone) homopolymer, or a poly(p-dioxanone-co-glycolide) copolymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel absorbable medical devices made from these novel polymer blends, as well as novel methods of manufacture.

Process for increasingly producing D-Lactide and meso lactide by depolymerizing by back biting polylactide (PLA) said process which comprises: (i) Depolymerizing polylactide into its corresponding dimeric cyclic esters by heating the polylactide in the presence of a catalyst system comprising a catalyst and a co-catalyst in a reaction zone at temperature and pressure at which the polylactide is molten; (ii) Forming a vapor product stream from the reaction zone; (iii) Removing the vapor product stream and optionally condense it; (iv) Recovering, either together or separately meso-lactide, D-lactide and L-lactide.

The invention provides a preparation method of a novel iron-oxide nanoparticle. The preparation method includes the steps: placing polylactic acid-polyethylene glycol and dimethyl formamide into water; adding 1-3-dimethylaminopropyl-3-ethyl carbodiimide hydrochloride and N-hydroxy succinimide into a reaction system; adding glucosamine hydrochloride into the reaction system; performing dialysis, purification and filtration; conjugating oleic acid with taxol, and then mixing the oleic acid with PLA-PEG-CO-NHC6H11O5 by equal molar ratio; adding Fe3O4@OA NPs into ethyl alcohol, adsorbing and separating the system by magnets, and adding tetrahydrofuran into the system to perform ultrasonic oscillation; adding OA-PTX-OA-PLA-PEG-CO-NHC6H11O5 into the system to perform ultrasonic oscillation; dropping the obtained reaction system into the water to perform ultrasonic oscillation, dialysis, purification and filtration. The invention further provides an application of the nanoparticle prepared bythe preparation method to tumor targeted diagnosis and treatment. The novel iron-oxide nanoparticle has dual functions of tumor treatment and tracing, and is high in sensitivity and strong in specificity and penetrability.

The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner / oil phase to an outer / water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of preferably basic / nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20% w / w is required. The release profile can be controlled by adjusting the degree of saturation of the outer / water phase with the organic solvent used in the inner / oil phase, the polymer concentration of the inner / oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.

A nanoparticle that has a membrane including a polylactide-block-poly(ethylene glycol)-block-polylactide (PLA-PEG-PLA) and a polyvinyl alcohol, a bovine serum albumin contacting the membrane on the outside of the nanoparticle, a targeting group attached to the outside of the nanoparticle, and a breast cancer therapeutic agent that is encapsulated by the membrane. A nanoparticle that consists of a membrane including a polylactide-block-poly(ethylene glycol)-block-polylactide (PLA-PEG-PLA) and a polyvinyl alcohol, a bovine serum albumin contacting the membrane on the outside of the nanoparticle, breast cancer therapeutic agent that is encapsulated by the membrane, and an anti-Her2 antibody attached to the outer surface of the nanoparticle. A range of a number average molecular weight of the PEG block is 800 Da to 3 kDa and a range of a number average molecular weight of each of the PLA blocks is from 1 kDa to 5 kDa.

The invention discloses a pluronic P85-containing polymer as well as a preparation method and application thereof, belongs to the field of biomedicines and discloses an amphiphilic block polymer with a novel chemical structure, and the amphiphilic block polymer contains a folic acid targeting group, takes polyoxyethylene-propylene oxide-ethylene oxide as a hydrophilic chain segment and takes polylactide as a hydrophobic chain segment, namely folic acid-polyoxyethylene-polypropylene-polyoxyethylene-polylactic acid (FA-P85-PLA) and the preparation method of the compound. The pluronic P85-containing polymer disclosed by the invention has good application prospects.